Race Oncology Ltd has released a press release.
December 2019 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Racura Oncology
- Race Receives $159k R&D Tax Incentive Refund
- Race reveals new strategy for cancer drug Bisantrene
- Appendix 4C - quarterly
- Prominent biotech investor leads investment in Race
- First patient treated in Bisantrene trial in Israel
Later from Racura Oncology
- Race Secures A$1.8m strategic placement
- Race starts preclinical breast cancer study for Bisantrene
- Managing Director Resignation
- Impressive 40% response in Phase II Bisantrene AML Trial
- Extension of time to repay loan through share buy-back
Follow Racura Oncology into a list and get an email when it puts out news.
Follow Racura Oncology